- Home
- ASND vs QGEN Comparison
ASND vs QGEN Comparison
Compare ASND & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | QGEN |
|---|---|---|
| Founded | 2006 | 1986 |
| Country | Denmark | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 10.2B |
| IPO Year | 2014 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ASND | QGEN |
|---|---|---|
| Price | $244.29 | $47.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $277.13 | $51.30 |
| AVG Volume (30 Days) | 751.3K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $98.99 | $7.99 |
| Revenue Next Year | $41.45 | $5.80 |
| P/E Ratio | ★ N/A | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $124.06 | $37.92 |
| 52 Week High | $242.43 | $57.82 |
Technical Indicators
Market Signals| Indicator | ASND | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.32 | 39.56 |
| Support Level | $190.49 | $47.40 |
| Resistance Level | N/A | $48.80 |
| Average True Range (ATR) | 10.44 | 0.93 |
| MACD | 1.37 | -0.23 |
| Stochastic Oscillator | 83.07 | 16.89 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).